Your browser doesn't support javascript.
loading
Implication of Haemodiafiltration Flow Rate on Amikacin Pharmacokinetic Parameters in Critically Ill Patients.
Ruiz-Ramos, Jesús; Villarreal, Esther; Gordon, Mónica; Martin-Cerezula, María; Broch, Maria Jesús; Remedios Marqués, María; Poveda, Jose Luis; Castellanos-Ortega, Álvaro; Ramírez, Paula.
Afiliação
  • Ruiz-Ramos J; Intensive Care Unit, Hospital Universitario y Politécnico La Fe, Avenida Fernando Abríl Martorell, Valencia, Spain.
  • Villarreal E; Intensive Care Unit, Hospital Universitario y Politécnico La Fe, Avenida Fernando Abríl Martorell, Valencia, Spain.
  • Gordon M; Intensive Care Unit, Hospital Universitario y Politécnico La Fe, Avenida Fernando Abríl Martorell, Valencia, Spain.
  • Martin-Cerezula M; Department of Pharmacy, Hospital Universitario y Politécnico La Fe, Avenida Fernando Abríl Martorell, Valencia, Spain.
  • Broch MJ; Intensive Care Unit, Hospital Universitario y Politécnico La Fe, Avenida Fernando Abríl Martorell, Valencia, Spain.
  • Remedios Marqués M; Department of Pharmacy, Hospital Universitario y Politécnico La Fe, Avenida Fernando Abríl Martorell, Valencia, Spain.
  • Poveda JL; Department of Pharmacy, Hospital Universitario y Politécnico La Fe, Avenida Fernando Abríl Martorell, Valencia, Spain.
  • Castellanos-Ortega Á; Intensive Care Unit, Hospital Universitario y Politécnico La Fe, Avenida Fernando Abríl Martorell, Valencia, Spain.
  • Ramírez P; Intensive Care Unit, Hospital Universitario y Politécnico La Fe, Avenida Fernando Abríl Martorell, Valencia, Spain.
Blood Purif ; 45(1-3): 88-94, 2018.
Article em En | MEDLINE | ID: mdl-29232669
ABSTRACT

BACKGROUND:

To analyse the effect of haemodiafiltration (CVVHDF) flow rate on amikacin pharmacokinetics and blood concentrations.

METHODS:

Prospective observational study. Patients receiving CVVHDF and amikacin treatment were included. Pharmacokinetic parameters were calculated using Bayesian analysis. Spearman correlation test was used in order to assess the influence of CVVHDF flux on amikacin minimum concentration (Cmin) and plasma clearance.

RESULTS:

Thirty patients undergoing CVVHDF procedures were included. The treatment with amikacin started at an initial mean dose of 12.4 (4.1) mg/kg/day. An association between the flow rate and Cmin value (r = 0.261; p = 0.161) and plasma clearance was found (r = 0.268; p = 0.152). Four patients (13.3%) were not able to achieve peak concentration over MIC value higher than 8. In 4 patients, amikacin had to be discontinued due to a high Cmin value.

CONCLUSIONS:

Amikacin clearance in patients with CVVHDF is affected by the flow rate used. Therefore, CVVHDF dose should be taken into account when dosing amikacin.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Amicacina / Hemodiafiltração Tipo de estudo: Observational_studies Limite: Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Blood Purif Ano de publicação: 2018 Tipo de documento: Article País de afiliação: Espanha

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Amicacina / Hemodiafiltração Tipo de estudo: Observational_studies Limite: Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Blood Purif Ano de publicação: 2018 Tipo de documento: Article País de afiliação: Espanha